Format

Send to

Choose Destination
Transfus Med Rev. 2017 Jan;31(1):1-10. doi: 10.1016/j.tmrv.2016.08.001. Epub 2016 Aug 9.

Zika Virus and the Blood Supply: What Do We Know?

Author information

1
New York Blood Center, New York, NY.
2
Columbia University Medical Center and New York Blood Center, New York, NY.
3
Johns Hopkins University, Baltimore, MD. Electronic address: ebloch2@jhmi.edu.

Abstract

Zika virus (ZIKV), a mosquito-borne Flavivirus and emerging infectious disease, is the focus of an international public health emergency after its rapid spread through the Americas and the Caribbean. Although most ZIKV infections are subclinical or characterized by mild febrile illness, ZIKV has been implicated in severe complications, most notably microcephaly in babies born to incident infected mothers during pregnancy. As yet, the extent to which ZIKV is transfusion transmissible remains undefined. Nonetheless, a high prevalence of asymptomatic infection during outbreaks, the demonstration of ZIKV in blood donors, and 4 possible cases of transfusion-transmitted ZIKV in Brazil have raised concern for risk to the blood supply. Consequently, a proactive response is underway by blood collection agencies, regulatory bodies, national funding agencies, and industry alike. Mitigation strategies differ between endemic and nonendemic areas. In the continental United States, the American Association of Blood Banks and Food and Drug Administration guidelines recommend travel-based deferral for those returning from affected areas, and nucleic acid testing is being initiated under an investigational new drug application in Puerto Rico and selected areas of the United States. Options are less clear for countries where autochthonous vector-borne transmission is active. The burden of Zika falls in low-resource countries where high cost and technical barriers associated with testing and pathogen reduction pose barriers to implementation. Additional strategies include maintaining selective inventory for high-risk recipients (eg, pregnant women). We review the available data as of July 2016 on ZIKV in relation to the blood supply including risk, mitigation strategies, and barriers to implementation in addition to the research that is needed to address current uncertainty.

KEYWORDS:

Arbovirus; Blood safety; Blood transfusion; Communicable diseases; Emerging; Transfusion-transmitted virus; Zika virus

PMID:
27569055
DOI:
10.1016/j.tmrv.2016.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center